article thumbnail

Windtree’s Istaroxime Scores in Cardiogenic Shock Trial

CardiacWire

Windtree Therapeutics’ istaroxime appears to have scored in its latest Phase 2b trial , showing that the steroidal drug significantly improves systolic blood pressure in cardiogenic shock patients. That could be a big deal in the cardiogenic shock space, which many believe is still in need of more effective treatments.

article thumbnail

Early Utilization of Mechanical Circulatory Support in Acute Myocardial Infarction Complicated by Cardiogenic Shock: The National Cardiogenic Shock Initiative

Journal of the American Heart Association

BackgroundAcute myocardial infarction complicated by cardiogenic shock (AMI‐CS) is associated with significant morbidity and mortality. Patients presented with a mean systolic blood pressure of 77.2±19.2 mm Hg, At 24 hours, mean systolic blood pressure improved to 103.9±17.8 mm Hg, mm Hg, lactate to 2.7±2.8 mmol/L,

article thumbnail

Prediction of In?Hospital Mortality for Ischemic Cardiogenic Shock Requiring Venoarterial Extracorporeal Membrane Oxygenation

Journal of the American Heart Association

BackgroundClinical outcome of ischemic cardiogenic shock (CS) requiring extracorporeal membrane oxygenation is highly variable, necessitating appropriate assessment of prognosis. However, a systemic predictive model estimating the mortality of refractory ischemic CS is lacking. Among 322 patients, 138 (42.9%) survived postdischarge.

article thumbnail

Magenta Medical, Developer of World’s Smallest Heart Pump, Closes $105M Financing Round

DAIC

It encompasses devices designed to mechanically unload the failing heart and augment cardiac output in the setting of dangerously low blood pressure, providing a bridge to recovery over a period of hours to days. FDA for two clinical indications: high-risk percutaneous coronary intervention (HR-PCI) and cardiogenic shock (CS).

article thumbnail

Clinical presentation, shock severity and mortality in patients with de novo versus acute?on?chronic heart failure?related cardiogenic shock

European Journal of Heart Failure

Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heart failure-related cardiogenic shock. ACHF-CS, acute-on-chronic failure-related cardiogenic shock; CI, confidence interval; DNHF-CS, de novo heart failure-related cardiogenic shock; HR, hazard ratio.

article thumbnail

Association between speckle tracking echocardiography and pressure-volume loops during cardiogenic shock development

Open Heart

LS correlated significantly with stroke volume, end-systolic elastance, systolic blood pressure, ventriculo-arterial coupling and arterial elastance. LS and LVOT VTI showed the strongest correlation to stroke work in unadjusted linear regression (r 2 =0.53 and r 2 =0.49, respectively).

article thumbnail

Tachycardia must make you doubt an ACS or STEMI diagnosis; put it all in clinical context

Dr. Smith's ECG Blog

He presented to the Emergency Department with a blood pressure of 111/66 and a pulse of 117. ACS and STEMI generally do not cause tachycardia unless there is cardiogenic shock. Then ACS (STEMI) might be primary; this might be cardiogenic shock. He had this ECG recorded. Are the lungs clear? The HCO3 was 8.

STEMI 52